All About World

08 »

ZolpidemSystematic (IUPAC) nameN,N,6-trimethyl-2-(4-methylphenyl)-imidazo(1,2-a)pyridine-3-acetamideIdentifiersCAS number82626-48-0ATC codeN05CF02PubChem5732DrugBankAPRD00095ChemSpider5530Chemical dataFormulaC19H21N3O Mol. mass307.395 g/molSMILESeMolecules & PubChemPharmacokinetic dataBioavailability70% (oral) 92% bound in plasmaMetabolismHepatic CYP3A4Half life2 to 2.6 hoursExcretion56% renal34% fecalTherapeutic considerationsPregnancy cat.B3(AU) B(US)Legal statusSchedule IV(US) Class C / POM (UK)RoutesOralZolpidem is a prescription medication used for the short-term treatment of insomnia, as well as some brain disorders. It is a short-acting nonbenzodiazepine hypnotic that potentiates gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, by binding to gamma-aminobutyric acid (GABAA) receptors at the same location as benzodiazepines. It works quickly (usually within 15 minutes) and has a short half-life (2–3 hours). Trade names of zolpidem include Adormix, Ambien, Ambien CR, Edluar, Damixan, Ivedal, Nytamel, Stilnoct, Stilnox, Sucedal, Zoldem, Zolnod and Zolpihexal.Its hypnotic effects are similar to those of the benzodiazepine class of drugs, but it is molecularly distinct from the classical benzodiazepine molecule and is classified as an imidazopyridine. Flumazenil, a benzodiazepine receptor antagonist, which is used for benzodiazepine overdose, can also reverse zolpidem's sedative/hypnotic and memory impairing effects.As an anticonvulsant and muscle relaxant, the beneficial effects start to emerge at 10 and 20 times the dose required for sedation, respectively. For that reason, it has never been approved for either muscle relaxation or seizure prevention. Such drastically increased doses are more inclined to induce one or more negative side-effects, including hallucinations and/or amnesia. (See below.)The patent 4382938 in the United States on zolpidem was held by the French pharmaceutical corporation Sanofi-Aventis. On April 23, 2007 the U.S. FDA approved 13 generic versions of zolpidem tartrate. Zolpidem is available from several generic manufacturers in the UK, as a generic from Sandoz in South Africa, as well as from other manufacturers such as Ratiopharm.Recently, zolpidem has been cited in various medical reports mainly in the United Kingdom as waking persistent vegetative state (PVS) patients, and dramatically improving the conditions of people with brain injuries.// UsesZolpidem is approved for the short-term (usually two to six weeks) treatment of insomnia, and it has been studied for nightly use up to six months in a single-blind trial published in 1991, an open-label study lasting 180 days published in 1992 (with continued efficacy in patients who had kept taking it as of 180 days after the end of the trial), and in an open-label trial lasting 179 days published in 1993.The United States Air Force uses zolpidem as a substitute for temazepam, under the trade name Ambien, as "no-go pills" to help pilots sleep after a mission.Zolpidem is also used off-label to treat restless leg syndrome, and, as is the case with many prescription sedative/hypnotic drugs, it is sometimes used by stimulant users to "come down" after the use of stimulants such as amphetamines (including methamphetamine), cocaine, and MDMA (ecstasy).Recently, the drug has been reported anecdotally to have positive effects for patients in persistent vegetative state. Results from phase IIa trials are expected in June 2007. The trials are being conducted by Regen Therapeutics of the UK, who have a patent pending on this new use for Zolpidem.A case study performed at the Toulouse University Hospital using PET showed zolpidem repeatably improves brain function and mobility of a patient immobilized by akinetic mutism caused by hypoxia. Mechanism of actionZolpidem due to its selective binding has very weak anxiolytic, myorelaxant and anticonvulsant properties but very strong hypnotic properties. Zolpidem binds with high affinity to the Ξ±1 containing GABAA receptors, about 10-fold lower affinity for those containing the Ξ±2, Ξ±3-GABAA receptor subunits, and with no appreciable affinity for Ξ±5 subunit containing receptors. Omega1 type GABAA receptors are the Ξ±1 containing GABAA receptors and Omega2 GABAA receptors are the Ξ±2, Ξ±3, Ξ±4, Ξ±5 and Ξ±6 containing GABAA receptors. Omega1 GABAA receptors are primarily found in the brain whereas omega2 receptors are primarily found in the spine. Thus zolpidem has a preferential binding for the GABAA-benzodiazepine receptor complex in the brain but a low affinity for the GABAA-benzodiazepine receptor complex in the spine.Like the vast majority of benzodiazepine-like molecules, zolpidem has no affinity for Ξ±4 and Ξ±6 subunit-containing receptors. Zolpidem positively modulates GABAA receptors, probably by increasing the GABAa receptor complexes apparent affinity for GABA, without affecting desensitization or peak current. Zolpidem increases slow wave sleep and caused no effect on stage 2 sleep in laboratory tests.A meta-analysis of the randomised controlled clinical trials that compared benzodiazepines against Z drugs has shown that there are few consistent differences between zolpidem and benzodiazepines in terms of sleep onset latency, total sleep duration, number of awakenings, quality of sleep, adverse events, tolerance, rebound insomnia, and daytime alertness. New researchZolpidem has recently been very strongly related to certain instances of patients in a minimally conscious coma state being brought to a fully conscious state. While it was initially given to these supposed permanent coma patients to put them to sleep, it actually brought them to a fully conscious state in which they were capable of communicating and interacting for the first time in years. CT scans have shown that the use of the drug actually does dramatically increase the activity in the frontal lobe of the brain in some patients in a minimally conscious state. Large-scale studies are currently being done to see whether it has the same universal effect on all or most patients in a minimally conscious state. It may be that zolpidem's ability to stimulate the brain, particularly in the semi-comatose, may be related to one of its side-effects, which sometimes causes sleepwalking and other activity while asleep, that appears to observers to be fully conscious activity. Tolerance, dependence and withdrawalA review medical publication found that long term use of zolpidem is associated with drug tolerance, drug dependence, rebound insomnia and CNS related adverse effects. It was recommended that zolpidem is used for short periods of time using the lowest effective dose. Non-pharmacological treatment options however, were found to have sustained improvements in sleep quality. Animal studies of the tolerance inducing properties have shown that in rodents zolpidem has less tolerance producing potential than benzodiazepines but in primates the tolerance producing potential of zolpidem was the same as that of benzodiazepines. Tolerance can develop in some people to the effects of zolpidem in just a few weeks. Abrupt withdrawal of zolpidem may cause delerium, seizures or other severe effects, especially if used for prolonged periods and at high dosages. When drug tolerance and physical dependence to zolpidem has developed, treatment usually entails a gradual dose reduction over a period of months in order to minimise withdrawal symptoms which can resemble those seen during benzodiazepine withdrawal. Failing that, an alternative method which may be necessary for some patients is a switch to a benzodiazepine equivalent dose of a longer acting benzodiazepine drug such as diazepam or chlordiazepoxide followed by a gradual reduction in dosage of the long acting benzodiazepine. Sometimes for difficult to treat patients an inpatient flumazenil rapid detoxification program can be used to detox from a zolpidem drug dependence or addiction. However, it should be noted that this treatment approach closely parallels that of the highly controversial rapid opiate detoxification therapy, which critics claim lacks long-term efficacy and can actually be detrimental to a patient's long-term recovery. Additionally, there have been many questions raised about the ethics as well as safety of rapid detox following a number of deaths resulting from the procedure.Alcohol has cross tolerance with GABAa receptor positive modulators such as the benzodiazepines and the nonbenzodiazepine drugs. For this reason alcoholics or recovering alcoholics may be at increased risk of physical dependency on zolpidem. Also, alcoholics and drug abusers may be at increased risk of abusing and or becoming psychologically dependent on zolpidem. Zolpidem should be avoided in those with a history of Alcoholism, drug misuse, or in those with history of physical dependency or psychological dependency on sedative-hypnotic drugs. Side effectsSide-effects at any dose may include:Anterograde amnesiaHallucinations, through all physical senses, of varying intensityDelusionsAltered thought patternsAtaxia or poor motor coordination, difficulty maintaining balanceEuphoria and/or dysphoriaIncreased appetiteDecreased libidoAmnesiaImpaired judgment and reasoningUninhibited extroversion in social or interpersonal settingsIncreased impulsivityWhen stopped, rebound insomnia may occurHeadaches, in some peopleA clinical trial found that after administration of zolpidem trial subjects tended to feel weak, fatigued and developed an antagonistic mood.Some users take zolpidem recreationally for some of these side-effects, notably sedation, hallucinations and euphoria. However, the abuse of zolpidem may be less common than benzodiazepine abuse. Zolpidem can become addictive if taken for extended periods of time, due to drug tolerance and physical dependence or the euphoria it can sometimes produce. As with most addictive drugs, a tolerance in the zolpidem user develops and increases a

Figures obtained by the Sunday Herald have revealed that six fatal suspected adverse drug reactions to zolpidem have been reported to Britain's medicines watchdog since 2001. One woman woke up with a paintbrush in her hand after having painted the front door.Several studies have linked Zolpidem, the active ingredient in the world’s most popular prescription sleep aid Ambien, to driving impairment and erratic behavior. A man took Stilnox at home and later found himself lying on a woman's couch wearing a dress.Drug zolpidem led to a dramatic improvement in the patient, almost completely disabled due to brain damage after an unsuccessful suicide attempts, reports New Scientist.A COMMONLY PRESCRIBED sleeping drug which actor Heath Ledger had admitted taking has been linked to six deaths in the UK."Stilnox (zolpidem, or Ambien in the US) has been causing weird sleep activity in Australia.baffling doctorsThe common sleeping pill zolpidem, sold in the US under the name Ambien, can reverse serious brain damage and wake up patients in persistent vegetative states"Last year, doctors across the country doled out millions of scripts for Ambien (zolpidem) and its relatives in the group known as hypnotic drugs.Buy cheap zolpidem tartrate online zolpidem ONLINE! DISCOUNTS

zolpidem

Zolpidem is a prescription medication used for the short-term treatment of insomnia, as well as some brain disorders. It is a short-acting nonbenzodiazepine hypnotic that ...

Read more...

Zolpidem - Wikipedia, the free encyclopedia

ZOLPIDEM est indiquΓ© dans l'insomnie occasionnelle, transitoire ou chronique.

Read more...

ZOLPIDEM - Zolpidem - Doctissimo

Π—ΠΎΠ»ΠΏΠΈΠ΄Π΅ΠΌ (Zolpidem) - инструкция ΠΏΠΎ ΠΏΡ€ΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡŽ. - ΠœΠ΅Π΄ΠΈΡ†ΠΈΠ½ΡΠΊΠ°Ρ Π±ΠΈΠ±Π»ΠΈΠΎΡ‚Π΅ΠΊΠ° ... Вся информация Π½Π° этом сайтС ...

Read more...

Π—ΠΎΠ»ΠΏΠΈΠ΄Π΅ΠΌ (Zolpidem) - инструкция ΠΏΠΎ ...

Zolpidem is een slaapmiddel. Het middel is ook bekend onder de merknaam Stilnoct. Het wordt door Sanofi-Aventis, Actavis en Ratiopharm op de markt gebracht.

Read more...

Zolpidem - Wikipedia

Warnings/Precautions: Should be used only after evaluation of potential causes of sleep disturbance. Failure of sleep disturbance to resolve after 7-10 days may indicate ...

Read more...